NI201800069A - Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il) -6-oxo-6, 7-dihidro-5h-pirrolo [2,3-d] pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares - Google Patents
Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il) -6-oxo-6, 7-dihidro-5h-pirrolo [2,3-d] pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovascularesInfo
- Publication number
- NI201800069A NI201800069A NI201800069A NI201800069A NI201800069A NI 201800069 A NI201800069 A NI 201800069A NI 201800069 A NI201800069 A NI 201800069A NI 201800069 A NI201800069 A NI 201800069A NI 201800069 A NI201800069 A NI 201800069A
- Authority
- NI
- Nicaragua
- Prior art keywords
- pharmaceutically acceptable
- derivatives
- compounds
- treatment
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona compuestos de la Fórmula (I) o una sal farmacéuticamente aceptable de los mismos, en la que X, Y, Z, R1, R2, R4, Ra y los subíndices m, p, y q son tal como se describen en el presente documento. Los compuestos o sus sales farmacéuticamente aceptables pueden modular la producción corporal de guanosín monofosfato cíclico ( "GMPc") y son generalmente adecuados para el tratamiento y la prevención de enfermedades que están asociadas con un equilibrio de GMPc perturbado tales como las enfermedades cardiovasculares, disfunción endotelial, disfunción diastólica, aterosclerosis, hipertensión, insuficiencia cardíaca, hipertensión pulmonar (grupo I de la OMS, II, III, IV), angina de pecho, trombosis, restenosis, infarto de miocardio, accidente cerebrovascular, insuficiencia cardiaca, fibrosis, hipertensión pulmonar, disfunción eréctil, asma, síndrome de dificultad respiratoria aguda (ARDS), enfermedad renal crónica, fibrosis quística , anemia de células falciformes, la esclerodermia, el síndrome de Raynaud, diabetes, retinopatía diabética, cirrosis hepática, enfermedad pulmonar obstructiva crónica (EPOC), lesión pulmonar aguda, fibrosis pulmonar o enfermedad pulmonar intersticial. La invención también proporciona composiciones farmacéuticas que comprenden compuestos de Fórmula (I) o sales farmacéuticamente aceptables de los mismos. La invención también se refiere a procedimientos para el uso de los compuestos o sus sales farmacéuticamente aceptables en el tratamiento y la prevención de las enfermedades mencionadas anteriormente y para la preparación de productos farmacéuticos para este fin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/098251 WO2017107052A1 (en) | 2015-12-22 | 2015-12-22 | Soluble guanylate cyclase stimulators |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201800069A true NI201800069A (es) | 2018-10-05 |
Family
ID=57758775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201800069A NI201800069A (es) | 2015-12-22 | 2018-06-13 | Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il) -6-oxo-6, 7-dihidro-5h-pirrolo [2,3-d] pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares |
Country Status (39)
Country | Link |
---|---|
US (2) | US10030027B2 (es) |
EP (1) | EP3394067B1 (es) |
JP (1) | JP6454448B2 (es) |
KR (1) | KR102191312B1 (es) |
CN (1) | CN108738320B (es) |
AR (1) | AR107154A1 (es) |
AU (1) | AU2016377364B2 (es) |
BR (1) | BR112018012579B8 (es) |
CA (1) | CA3009193C (es) |
CL (1) | CL2018001671A1 (es) |
CO (1) | CO2018006300A2 (es) |
CR (1) | CR20180330A (es) |
CY (1) | CY1123173T1 (es) |
DK (1) | DK3394067T3 (es) |
DO (1) | DOP2018000153A (es) |
EA (1) | EA036445B1 (es) |
EC (1) | ECSP18054606A (es) |
ES (1) | ES2794654T3 (es) |
HK (1) | HK1255028A1 (es) |
HR (1) | HRP20200857T1 (es) |
HU (1) | HUE049941T2 (es) |
IL (1) | IL260020B (es) |
LT (1) | LT3394067T (es) |
ME (1) | ME03748B (es) |
MX (2) | MX2018007728A (es) |
MY (1) | MY194021A (es) |
NI (1) | NI201800069A (es) |
PE (1) | PE20181802A1 (es) |
PH (1) | PH12018501342A1 (es) |
PL (1) | PL3394067T3 (es) |
PT (1) | PT3394067T (es) |
RS (1) | RS60344B1 (es) |
SG (1) | SG11201805272XA (es) |
SI (1) | SI3394067T1 (es) |
SV (1) | SV2018005715A (es) |
TN (1) | TN2018000219A1 (es) |
TW (1) | TWI724079B (es) |
UA (1) | UA122264C2 (es) |
WO (2) | WO2017107052A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
CA3005727A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators |
PE20230731A1 (es) | 2015-12-22 | 2023-05-03 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
WO2017200857A1 (en) | 2016-05-18 | 2017-11-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
PE20190731A1 (es) | 2016-06-20 | 2019-05-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
BR112019012957A2 (pt) | 2016-12-22 | 2019-11-26 | Incyte Corp | derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1 |
MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
KR102615821B1 (ko) * | 2017-04-11 | 2023-12-21 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 불소-치환된 인다졸 화합물 및 이의 용도 |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
HRP20230090T1 (hr) | 2018-03-30 | 2023-03-17 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
US20210052528A1 (en) | 2018-04-30 | 2021-02-25 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
PE20230407A1 (es) | 2019-11-11 | 2023-03-07 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
ES2210728T3 (es) | 1997-03-07 | 2004-07-01 | Metabasis Therapeutics, Inc. | Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa. |
WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE19744027A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DK1112275T3 (da) | 1998-09-09 | 2003-11-24 | Metabasis Therapeutics Inc | Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase |
JP2004513076A (ja) | 2000-07-25 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療で有用なn−置換インドール類 |
JP4181408B2 (ja) | 2001-01-30 | 2008-11-12 | メルク エンド カムパニー インコーポレーテッド | 肥満、糖尿病及び脂質異常を治療するためのアシルスルファミド類 |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
JP4340232B2 (ja) | 2002-08-29 | 2009-10-07 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病活性を有するインドール類 |
MXPA05002303A (es) | 2002-08-29 | 2005-06-08 | Merck & Co Inc | Indoles con actividad antidiabetica. |
WO2004066963A2 (en) | 2003-01-17 | 2004-08-12 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
WO2009000087A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
KR101404781B1 (ko) | 2007-06-28 | 2014-06-12 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 반도체 장치의 제조 방법 |
JP2010533712A (ja) | 2007-07-19 | 2010-10-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物としてのベータカルボリン誘導体 |
WO2009032249A1 (en) | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
WO2009042053A2 (en) | 2007-09-21 | 2009-04-02 | Merck & Co., Inc. | Neuromedin u receptor agonists and uses thereof |
EP2373317B1 (en) * | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
SG185777A1 (en) * | 2010-05-27 | 2012-12-28 | Merck Sharp & Dohme | Soluble guanylate cyclase activators |
EP2708539A1 (de) | 2010-07-09 | 2014-03-19 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
CN103619845B (zh) | 2011-04-21 | 2016-08-17 | 拜耳知识产权有限责任公司 | 氟烷基取代的吡唑并吡啶及其用途 |
ES2592267T3 (es) | 2011-05-06 | 2016-11-29 | Bayer Intellectual Property Gmbh | Imidazopiridinas e imidazopiridazinas sustituidas y su uso |
MX2014000029A (es) | 2011-07-06 | 2014-02-17 | Bayer Ip Gmbh | Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de guanilato ciclasas solubles. |
WO2013030288A1 (de) | 2011-09-02 | 2013-03-07 | Bayer Intellectual Property Gmbh | Substituierte annellierte pyrimidine und ihre verwendung |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
US9605008B2 (en) | 2013-07-10 | 2017-03-28 | Bayer Pharma Aktiengesellschaft | Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2015088885A1 (en) * | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2015187470A1 (en) | 2014-06-04 | 2015-12-10 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
WO2016044446A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
MX2018007152A (es) | 2015-12-14 | 2018-08-15 | Ironwood Pharmaceuticals Inc | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
CA3012001A1 (en) | 2016-02-01 | 2017-08-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash) |
-
2015
- 2015-12-22 WO PCT/CN2015/098251 patent/WO2017107052A1/en active Application Filing
-
2016
- 2016-12-20 AR ARP160103930A patent/AR107154A1/es unknown
- 2016-12-20 PL PL16823455T patent/PL3394067T3/pl unknown
- 2016-12-20 ME MEP-2020-103A patent/ME03748B/me unknown
- 2016-12-20 RS RS20200620A patent/RS60344B1/sr unknown
- 2016-12-20 BR BR112018012579A patent/BR112018012579B8/pt active IP Right Grant
- 2016-12-20 CN CN201680075365.8A patent/CN108738320B/zh active Active
- 2016-12-20 CA CA3009193A patent/CA3009193C/en active Active
- 2016-12-20 MY MYPI2018001031A patent/MY194021A/en unknown
- 2016-12-20 SG SG11201805272XA patent/SG11201805272XA/en unknown
- 2016-12-20 HU HUE16823455A patent/HUE049941T2/hu unknown
- 2016-12-20 UA UAA201808060A patent/UA122264C2/uk unknown
- 2016-12-20 JP JP2018532431A patent/JP6454448B2/ja active Active
- 2016-12-20 TN TNP/2018/000219A patent/TN2018000219A1/en unknown
- 2016-12-20 MX MX2018007728A patent/MX2018007728A/es active IP Right Grant
- 2016-12-20 KR KR1020187020705A patent/KR102191312B1/ko active IP Right Grant
- 2016-12-20 CR CR20180330A patent/CR20180330A/es unknown
- 2016-12-20 SI SI201630769T patent/SI3394067T1/sl unknown
- 2016-12-20 PE PE2018001156A patent/PE20181802A1/es unknown
- 2016-12-20 PT PT168234557T patent/PT3394067T/pt unknown
- 2016-12-20 EP EP16823455.7A patent/EP3394067B1/en active Active
- 2016-12-20 LT LTEP16823455.7T patent/LT3394067T/lt unknown
- 2016-12-20 DK DK16823455.7T patent/DK3394067T3/da active
- 2016-12-20 US US15/384,429 patent/US10030027B2/en active Active
- 2016-12-20 WO PCT/US2016/067654 patent/WO2017112617A1/en active Application Filing
- 2016-12-20 ES ES16823455T patent/ES2794654T3/es active Active
- 2016-12-20 AU AU2016377364A patent/AU2016377364B2/en active Active
- 2016-12-20 TW TW105142318A patent/TWI724079B/zh active
- 2016-12-20 EA EA201891303A patent/EA036445B1/ru not_active IP Right Cessation
-
2018
- 2018-06-13 IL IL260020A patent/IL260020B/en active IP Right Grant
- 2018-06-13 NI NI201800069A patent/NI201800069A/es unknown
- 2018-06-18 CO CONC2018/0006300A patent/CO2018006300A2/es unknown
- 2018-06-19 SV SV2018005715A patent/SV2018005715A/es unknown
- 2018-06-19 CL CL2018001671A patent/CL2018001671A1/es unknown
- 2018-06-21 MX MX2020011080A patent/MX2020011080A/es unknown
- 2018-06-21 PH PH12018501342A patent/PH12018501342A1/en unknown
- 2018-06-22 DO DO2018000153A patent/DOP2018000153A/es unknown
- 2018-06-27 US US16/019,964 patent/US10428076B2/en active Active
- 2018-07-19 EC ECSENADI201854606A patent/ECSP18054606A/es unknown
- 2018-11-06 HK HK18114149.1A patent/HK1255028A1/zh unknown
-
2020
- 2020-05-28 HR HRP20200857TT patent/HRP20200857T1/hr unknown
- 2020-06-16 CY CY20201100547T patent/CY1123173T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201800069A (es) | Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il) -6-oxo-6, 7-dihidro-5h-pirrolo [2,3-d] pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares | |
CO6640255A2 (es) | Activadores de guanilato ciclasa soluble | |
CY1121452T1 (el) | Παραγωγα πουρινης για τη θεραπευτικη αντιμετωπιση ιικων λοιμωξεων | |
BR112013030909A2 (pt) | compostos de imidazopiridina | |
CO6660514A2 (es) | Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih | |
IN2014CN00989A (es) | ||
AR087546A1 (es) | Hemifumarato de tenofovir alafenamida | |
AR061386A1 (es) | Pirrolopiridinas sustituidas como moduladores de proteina quinasa, una composicion farmaceutica que las comprende, un proceso y un compuesto intermediario para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
BR112013003004A2 (pt) | processos para a preparação de tubulisinas | |
CL2013002546A1 (es) | Compuestos derivados de benzodioxano con actividad inhibidora de leucotrieno a4 hidrolasa(lat4h), composicion farmaceutica que los comprende, uso para preparar un medicamento para el tratamiento de enfermedades cardiovasculares tales como ateroesclerosis, infarto de miocardio, apoplejia, aneurisma de aorta, hipertension pulmonar arterial, entre otras. | |
PE20151084A1 (es) | Derivados de pirimidinona inhibidoras de la elastasa de neutrofilos humanos (hne) | |
AR092500A1 (es) | Solucion de limpieza de colon | |
BR112016016321A2 (pt) | Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica | |
CY1116142T1 (el) | Εισπνεομενο φαρμακο που περιλαμβανει τιοτροπιο | |
BR112017016599A2 (pt) | concentrado de adjuvante aquoso, e, formulação de herbicida pulverizável. | |
AR089860A1 (es) | Analogos de la grelina | |
CL2013000021A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable. | |
ECSP12012358A (es) | Activadores de guanilato ciclasa soluble | |
Prodius | Showcasing research from Dr Denis Prodius (Alexander von Humboldt Fellow, Moldova) and Prof. Annie K. Powell’s Group/Institute of Nanotechnology, Karlsruhe Institute of Technology, Germany | |
TH133571B (th) | หน้าตัด | |
TH101892B (th) | ของเล่นสำหรับเด็ก | |
TH125414B (th) | แผ่นบันได | |
CN302173260S (zh) | 游戏床二道锁扣 | |
CN302001523S (zh) | 栏杆(圣罗兰) |